Ubisoft Entertainment SA (UBI):企業の財務・戦略的SWOT分析

◆英語タイトル:Ubisoft Entertainment SA (UBI) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA8010310
◆発行会社(調査会社):GlobalData
◆発行日:2018年1月4日
◆ページ数:33
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:技術・通信
◆販売価格オプション(消費税別)
Single UserUSD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Ubisoft Entertainment SA (UBI) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Ubisoft Entertainment SA (Ubisoft) is a computer gaming company. It is one of the leading independent video games publishers in the world. The company carries out research, development, publishing and distribution of video games for portable and home consoles, the PC, smartphones and tablets in both physical and online formats. The company’s product portfolio includes Rayman, Tom Clancy, Ghost Recon, Splinter Cell, Prince of Persia, Child of Eden, Shaun White, Driver and The Settlers. It also distributes games developed by other companies. It distributes products across North and South America, Europe, the Middle East and Asia-Pacific. Ubisoft is headquartered in Montreuil, France.

Ubisoft Entertainment SA Key Recent Developments

Sep 05,2017: Ubisoft announces plans to open two new studios in Quebec over the next decade
Sep 02,2017: Ubisoft to announce 100 new jobs in Saguenay, invest $100 million
Jul 18,2017: UbiSoft Entertainment Q1 sales increase
Jul 07,2017: Ubisoft to appoint two new directors, giving board independent majority

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Section 1 – About the Company 5
Ubisoft Entertainment SA – Key Facts 5
Ubisoft Entertainment SA – Key Employees 6
Ubisoft Entertainment SA – Key Employee Biographies 7
Ubisoft Entertainment SA – Major Products and Services 8
Ubisoft Entertainment SA – History 9
Ubisoft Entertainment SA – Company Statement 11
Ubisoft Entertainment SA – Locations And Subsidiaries 12
Head Office 12
Other Locations & Subsidiaries 12
Section 2 – Company Analysis 14
Company Overview 14
Ubisoft Entertainment SA – Business Description 14
Ubisoft Entertainment SA – Corporate Strategy 15
Ubisoft Entertainment SA – SWOT Analysis 16
SWOT Analysis – Overview 16
Ubisoft Entertainment SA – Strengths 16
Ubisoft Entertainment SA – Weaknesses 17
Ubisoft Entertainment SA – Opportunities 18
Ubisoft Entertainment SA – Threats 19
Ubisoft Entertainment SA – Key Competitors 20
Section 3 – Company Financial Ratios 21
Financial Ratios – Capital Market Ratios 21
Financial Ratios – Annual Ratios 22
Performance Chart 25
Financial Performance 25
Financial Ratios – Interim Ratios 26
Financial Ratios – Ratio Charts 27
Section 4 – Company’s Recent Developments 28
Jul 18, 2017: UbiSoft Entertainment Q1 sales increase 28
Section 5 – Appendix 29
Methodology 29
Ratio Definitions 29
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
Ubisoft Entertainment SA, Key Facts 5
Ubisoft Entertainment SA, Key Employees 6
Ubisoft Entertainment SA, Key Employee Biographies 7
Ubisoft Entertainment SA, Major Products and Services 8
Ubisoft Entertainment SA, History 9
Ubisoft Entertainment SA, Other Locations 12
Ubisoft Entertainment SA, Subsidiaries 13
Ubisoft Entertainment SA, Key Competitors 20
Ubisoft Entertainment SA, Ratios based on current share price 21
Ubisoft Entertainment SA, Annual Ratios 22
Ubisoft Entertainment SA, Annual Ratios (Cont...1) 23
Ubisoft Entertainment SA, Annual Ratios (Cont...2) 24
Ubisoft Entertainment SA, Interim Ratios 26
Currency Codes 29
Capital Market Ratios 29
Equity Ratios 30
Profitability Ratios 30
Cost Ratios 31
Liquidity Ratios 31
Leverage Ratios 32
Efficiency Ratios 32

★海外企業調査レポート[Ubisoft Entertainment SA (UBI):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • NxStage Medical Inc (NXTM):企業の製品パイプライン分析2018
    Summary NxStage Medical Inc (NxStage) is a medical technology company that develops, manufactures and markets conventional dialysis machines. The company develops products for the treatment of end-stage renal disease and acute kidney failure. It provides products such as nxstage system one, cartridg …
  • Sermsuk Public Company Limited:企業の戦略・SWOT・財務分析
    Sermsuk Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary Sermsuk Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Bank of America Corp:企業の戦略・SWOT・財務分析
    Bank of America Corp - Strategy, SWOT and Corporate Finance Report Summary Bank of America Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Nuformix Plc (NFX):製薬・医療:M&Aディール及び事業提携情報
    Summary Nuformix Plc (Nuformix), formerly Levrett plc, is a pharmaceutical company which develops cocrystal forms of approved small molecules. Its product candidates which are in clinical and pre-clinical development include NXP001, NXP002, and NXP003 for the treatment of oncology supportive care an …
  • Juvenile Diabetes Research Foundation-医療機器分野:企業M&A・提携分析
    Summary Juvenile Diabetes Research Foundation (JDRF) is a research organization that offers funding services for type one diabetes. The organization conducts clinical trials for curing, preventing and treating for type one diabetes and its complications; and researching new drugs for patients to man …
  • Acron (AKRN):企業の財務・戦略的SWOT分析
    Summary Acron produces and commercializes mineral fertilizers. The company offers ammonium nitrate, urea, ammonia, apatite concentrate, methanol, formalin, urea-formaldehyde resins, melamine-urea-formaldehyde resins and dipping resins, cerium, lanthanum, neodymium and didymium. Its products finds ap …
  • Cydan Development Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Cydan Development Inc (Cydan) is an orphan drug accelerator dedicated to advancing therapies for rare genetic diseases. The company identifies assets with biology and proof-of-concept data in vivo models from academic circles, industry, and other sources. It offers various technology platfor …
  • Alnylam Pharmaceuticals Inc (ALNY):企業の財務・戦略的SWOT分析
    Alnylam Pharmaceuticals Inc (ALNY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Kansai Paint Co Ltd (4613):企業の財務・戦略的SWOT分析
    Kansai Paint Co Ltd (4613) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Toyo Seikan Group Holdings, Ltd.
    Toyo Seikan Group Holdings, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Toyo Seikan Group Holdings, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Pelago Bioscience AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Pelago Bioscience AB (Pelago Bioscience) is a developer of patented cellular thermal shift assay for use in determination and quantification of drug–target interactions. The company utilizes patented CETSA technology which enables direct, in situ physiologically relevant measurements of targ …
  • Industrija nafte dd (INA-R-A):企業の財務・戦略的SWOT分析
    Industrija nafte dd (INA-R-A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Immatics Biotechnologies GmbH:企業のM&A・事業提携・投資動向
    Immatics Biotechnologies GmbH - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Immatics Biotechnologies GmbH Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Ontario Municipal Employees Retirement System:電力:M&Aディール及び事業提携情報
    Summary Ontario Municipal Employees Retirement System (OMERS) offers pension benefits to government employees, beneficiaries, and retirees from diverse sectors such as municipalities, libraries, police and fire departments, schools, and other agencies in Ontario. It is sponsored by OMERS Sponsors Co …
  • Sygnity SA (SGN):企業の財務・戦略的SWOT分析
    Sygnity SA (SGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • PG&E Corporation (PCG):企業の財務・戦略的SWOT分析
    PG&E Corporation (PCG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Exact Sciences Corp (EXAS)-製薬・医療分野:企業M&A・提携分析
    Summary Exact Sciences Corp (Exact) is a molecular diagnostic company that focuses on the early detection and prevention of various cancers. The company’s flagship product, Cologuard test is a non-invasive stool-based deoxyribonucleic acid (DNA) screening product indicated for the early detection of …
  • Aditya Birla Retail Ltd:企業の戦略的SWOT分析
    Aditya Birla Retail Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Humanigen Inc (HGEN):製薬・医療:M&Aディール及び事業提携情報
    Summary Humanigen Inc (Humanigen), formerly KaloBios Pharmaceuticals Inc is a biopharmaceutical company that develops proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company provides Ifabotuzumab(anti-EphA3) and Lenzilumab(anti-GM-CSF) recombinant monoclonal antibodi …
  • Companhia Energetica de Sao Paulo (CESP6):企業の財務・戦略的SWOT分析
    Companhia Energetica de Sao Paulo (CESP6) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆